Detailed explanation of the functions and efficacy of Glasdegib

Glasdegib is a new type of targeted drug, mainly used in combination with low-dose cytarabine (cytarabine) to treat newly diagnosed acute myeloid leukemia (AML) in adults aged ≥75 years or who are unable to receive intensive induction chemotherapy due to comorbidities. As a potent and selective inhibitor of the hedgehog signaling pathway, Glasgib acts by binding to smooth muscle (SMO) receptors, thereby regulating the pathway.

The Hedgehog signaling pathway plays a key role in the maintenance of neural and skin stem cells. When a specific ligand binds to the transmembrane receptor patched (PTCH1), it activates the transcriptional regulators GL11 and GL12 and regulates gene expression through SMO-mediated signaling.

Studies have shown that abnormal activation of this signaling pathway is closely related to a variety of cancers, including chronic myelogenous leukemia, medulloblastoma, and basal cell carcinoma, because these abnormal changes often lead to excessive cell proliferation. In preclinical studies, Glasgib was shown to significantly reduce leukemia stem cell burden in xenograft models and reduce the population of cells expressing leukemia stem cell markers. This finding provides strong support for its potential in clinical applications.

In clinical trials, Glasgib was able to significantly reduce the expression of glioma-related transcriptional regulator GL11 in the skin, by more than 80%. The study also found that approximately 8% of acute myeloid leukemia patients achieved morphologic complete remission, while 31% achieved stable disease.

More importantly, the latest clinical trial confirmed that treatment with Glasgib improved the overall survival of patients to8.3 months, which is almost twice the survival of patients who received low-dose cytarabine. However, it should be noted that patients taking Glasgib may experience dose-dependent QTc prolongation, so regular ECG monitoring is required during clinical use to ensure safety.

Reference materials:https://go.drugbank.com/drugs/DB11978